https://www.hsbcinnovationbanking.com/us/en/business-stage/hsbc-healthcare-reports 

Hosts:

Joseph Snyder

Head of Talent and Co-Founder, Lifeblood

https://www.linkedin.com/in/josephasnyder1/

Cristiano Fontana

Head of Advisory, Lifeblood

https://www.linkedin.com/in/cristiano-fontana-medtech-businessdevelopment/

Guests:

Jonathan Norris

Managing Director, VC Relationship Managment, HSBC Innovation Banking

Jonathan Norris is a Managing Director at HSBC Innovation, with over two decades of experience in the healthcare and life sciences sector. A former litigation attorney, Jonathan has been immersed in healthcare investing since 1999, with a particular focus on equity and debt strategy across BioPharma, Medical Devices, Diagnostics/Tools, and Digital Health.

At HSBC Innovation, Jonathan advises both investors and executives by analyzing historical and current market trends, including venture investments, IPO activity, and M&A. He regularly supports C-level leadership with business planning, exit strategy, and access to capital, and is known for his insightful thought leadership on healthcare venture funding and deal flow.

Jonathan has authored numerous analyses on the flow of capital into the healthcare ecosystem and continues to be a trusted voice in the industry, helping shape strategic decision-making for both startups and investors.

https://www.linkedin.com/in/jonathan-norris-248556/

Hosts:

Joseph Snyder

Head of Talent and Co-Founder, Lifeblood

https://www.linkedin.com/in/josephasnyder1/

Cristiano Fontana

Head of Advisory, Lifeblood

https://www.linkedin.com/in/cristiano-fontana-medtech-businessdevelopment/

Guests:

Kavita Bouknight

CEO, Match Health Collective

Kavita Bouknight is the CEO of Match Health Collective which specializes in MedTech marketing, messaging, and design. Their work focuses on building compelling brand identities, developing cohesive visual design, crafting strategic messaging frameworks, and creating pitch-ready content and go-to-market strategies to drive visibility and accelerate adoption.

https://www.linkedin.com/in/kavitabouknight/ 

Martin Gomez

Partner, Goodwin

Co-leading the MedTech and Artificial Intelligence practice across IP, company formation, licensing, fundraising, an strategic transactions or exits.

From FDA expectations to real-world applications, we explore what’s hype, what’s real, and what founders need to know to integrate AI responsibly. Tune in as they explore how AI is shaping product development, regulatory hurdles, and investor expectations across the MedTech landscape.

https://www.linkedin.com/in/martin-gomez-898556113/

Hosts:
 
Joseph Snyder
 
Head of Talent and Co-Founder, Lifeblood

https://www.linkedin.com/in/josephasnyder1/

Cristiano Fontana
 
Head of Advisory, Lifeblood

 https://www.linkedin.com/in/cristiano-fontana-medtech-businessdevelopment/
 
Guests:

Darcy Bachert

CEO, Prolucid

Darcy Bachert is the Founder and CEO of Prolucid, an ISO-13485 certified software engineering firm that specializes in custom medical software development. Over the past 17 years Darcy has grown Prolucid to a team of 25, supporting innovative MedTech companies across the world in successfully bringing their applications and devices to market

https://www.linkedin.com/in/darcybachert/

Robert Hamilton

CEO, NeuraSignal Inc.

Robert is a seasoned healthcare entrepreneur, executive, and engineer with a deep commitment to driving transformative innovation in medicine. With a passion for aligning bold vision with high-performing teams, he has spent his career tackling some of the most complex challenges in healthcare.

Robert’s vision and leadership continue to place NeuraSignal at the forefront of AI-powered neurodiagnostics, advancing the future of brain health.

https://www.linkedin.com/in/hamiltonrobert/

Carmen Brown

Senior Manager of Regulatory Affairs, Proxima

Carmen Brown is a Senior Regulatory Affairs Manager at Proxima Clinical Research, Inc. with 10 years of work experience in the pharmaceutical and medical device industry.  Carmen has a master’s in public health and a bachelor’s degree in chemistry. At Proxima, Carmen has worked on both drug products and medical devices specializing in combination products. Her expertise spans a wide variety of therapeutic areas including oncology and IVDs that have included AI/ML. 

https://www.linkedin.com/in/carmen-brown-068462a6/

Hosts:

Joseph Snyder

Head of Talent and Co-Founder, Lifeblood

https://www.linkedin.com/in/josephasnyder1/

Cristiano Fontana

Head of Advisory, Lifeblood

https://www.linkedin.com/in/cristiano-fontana-medtech-businessdevelopment/

Guests:

Darcy Bachert

CEO, Prolucid

Darcy Bachert is the Founder and CEO of Prolucid, an ISO-13485 certified software engineering firm that specializes in custom medical software development. Over the past 17 years Darcy has grown Prolucid to a team of 25, supporting innovative MedTech companies across the world in successfully bringing their applications and devices to market

https://www.linkedin.com/in/darcybachert/

Alex Condon

COO, Matrix One

Alex Condon is the former co-founder of Galen Data, a globally compliant medical device cloud platform that provides connectivity, centralizes data, and provides analytics for the next generation of medical device companies, acquired by Matrix one.

https://www.linkedin.com/in/alexcondon/

Marty Gomez

Partner, Goodwin

Marty Gomez co-leads the MedTech and Artificial Intelligence practice at Goodwin across IP, company formation, licensing, fundraising, an strategic transactions or exits. 

https://www.linkedin.com/in/martin-gomez-898556113/

Hosts:

Joseph Snyder

Head of Talent and Co-Founder, Lifeblood

https://www.linkedin.com/in/josephasnyder1/

Cristiano Fontana

Head of Advisory, Lifeblood

https://www.linkedin.com/in/cristiano-fontana-medtech-businessdevelopment/

Guests:

Tim Jones

CEO, Symphysis Medical

Tim Jones is the CEO of SymPhysis Medical, an Irish MedTech start-up developing innovative solutions for the management of pleural effusions. Prior to founding SymPhysis Medical, Tim held key roles at Medtronic, where he gained hands-on experience in global MedTech operations, product development, and market access strategies within one of the world’s leading medical technology companies. At SymPhysis, Tim has led the company from early-stage concept through clinical validation, securing private investment and highly competitive non-dilutive funding, while earning international recognition for advancing patient-centric design in MedTech innovation.

https://www.linkedin.com/in/tim-jones-1a004040/

Daniel O-Mahony

Partner, Seroba

Daniel O’Mahony is a Partner at Seroba, where he leverages over two decades of experience in life sciences, spanning product development, strategic planning, licensing, corporate venturing, and intellectual property commercialisation. He began his investment career in corporate venture at Elan Corporation and later became a partner at Kernel Capital, before joining Seroba in 2009.

With a strong foundation in both academia and technology transfer, Daniel previously held research and teaching roles at Trinity College Dublin, the Geisinger Clinic in Pennsylvania, and University College Dublin. He also led the Technology Transfer Office at the University of Galway, where he secured several high-value licensing agreements.

https://www.linkedin.com/in/daniel-o-mahony-b02a1413/

Joey Mason

Venture Partner, Claret Capital Partners

Joey Mason has spent 30 years working in life sciences as an investor, entrepreneur, financier, director, mentor and advisor. He is currently a Venture Partner at Claret Capital Partners, a London-based venture debt firms. Joey also serves as a Venture Advisor to Sofinnova Partners, one of Europe’s leading healthcare investment firm. 

Joey has significant experience in most segments of the industry – medtech, pharma/ biotech, diagnostics, health IT and techbio. He has served on the boards of 20 private and public companies in Ireland, Europe and the USA and also on the board of EVCA (InvestEurope), the trade association for the private equity industry in Europe. In 2021, he co-founded Duplex Capital Partners to advise companies innovating in the digitalisation of life sciences. Prior to this he led a Life Science fund at M Ventures, Merck KGaA’s corporate venture arm, from 2018 – 2020 in Amsterdam, having spent 10 years at Delta Partners from 2004, where he was responsible for its most profitably exited investment. 

https://www.linkedin.com/in/joey-mason/

Hosts:

Joseph Snyder

Head of Talent and Co-Founder, Lifeblood

https://www.linkedin.com/in/josephasnyder1/

Cristiano Fontana

Head of Advisory, Lifeblood

https://www.linkedin.com/in/cristiano-fontana-medtech-businessdevelopment/

Guests:

Paul Grand

Founder & CEO, MedTech Innovator

Paul is the founder and CEO of MedTech Innovator. He created and managed MedTech Innovator as a program within RCT Ventures from 2013 – 2016. In 2016, with the financial support of RCT and other sponsors, Paul left to run MedTech Innovator as a stand-alone company. He spent 11 years as Director and Managing Director at RCT Ventures, the investment arm of Research Corporation Technologies, Inc. Prior to RCT, Paul was co-founder and CEO of startups in the MedTech, pharma, and tech sectors.

https://www.linkedin.com/in/paulgrand/

Stephen Levin, Editor-in-Chief, Medtech Strategist/Market Pathways

Managing Partner, Innovation In Medtech, LLC

Stephen Levin has spent more than 25 years covering the life sciences industry, writing and speaking primarily on medical technology worldwide.  In 2014, Levin and his long-time colleague, David Cassak, launched Innovation In Medtech, LLC, which features a pair of global medtech publications, MEDTECH STRATEGIST (focusing on business development) and MARKET PATHWAYS (covering medtech regulatory, reimbursement and policy issues), along with industry-leading investor conferences in Dublin, Ireland, and California. 

Levin formerly was Editor-in-Chief/Medical Devices at Elsevier Business Intelligence (EBI), from 2008 until EBI was acquired by Informa in 2013.  At EBI, he directed the editorial coverage for the company’s medtech publications, including IN VIVO, START-UP, MEDTECH INSIGHT, THE GRAY SHEET, and THE SILVER SHEET, along with the content for the Investment In Innovation (IN3) series of medical device partnering conferences.  EBI was formed in 2008 when Elsevier acquired Windhover Information and combined Windhover with FDC Reports.  He had joined Windhover in 1997, where as Executive Editor, he supervised the editorial operations of IN VIVO, START-UP, and MEDTECH INSIGHT, while also covering the device industry, distribution, and legal issues.  He also served as the company’s General Counsel.  

https://www.linkedin.com/in/stephen-levin-3415a591/

Ken Nelson

Partner, MedTech Advantage Fund

Ken Nelson is a seasoned leader and innovator in digital health and MedTech, with over 20 years of experience spanning Fortune 500 companies, high-growth startups, and successful exits. He has played a pivotal role in shaping the commercial success of groundbreaking technologies in digital health, wearables, and cardiac remote patient monitoring.

Ken’s leadership helped build three of the top four market share companies in the cardiac monitoring space, including BioTelemetry (#1, acquired by Philips for $2.8B), iRhythm (#2, IPO), and Bardy Diagnostics (#4, acquired by HillRom for over $400). At Bardy Diagnostics, he led global commercialization of the CAM Patch, securing over $35M in venture funding and driving the company’s rapid growth. 

Ken brings deep expertise in commercialization, startup scaling, strategic partnerships, and M&A. His specialties include sales and marketing leadership, disruptive product launches, venture fundraising, and strategic operations across cardiology, electrophysiology, and diagnostics.

https://www.linkedin.com/in/ken-nelson-56aaa34/

Hosts:

Joseph Snyder

Head of Talent and Co-Founder, Lifeblood

https://www.linkedin.com/in/josephasnyder1/

Cristiano Fontana

Head of Advisory, Lifeblood

https://www.linkedin.com/in/cristiano-fontana-medtech-businessdevelopment/

Guests:

David Uffer

Managing Director, Trinity Life Sciences

David brings over 30 years of executive level experience dedicated to MedTech to Trinity. He has experience across strategy consulting, transaction advisory, venture investing, as well as HEOR, market access and clinical affairs advisory all focused on device, diagnostics and digital health. 

Before joining Trinity David led MedTech portfolio and investing at General Inception, a venture capital firm. Prior to that, Dave spent five years leading the MedTech practice as Senior Partner at Alira Health, a global advisory firm with practices across all healthcare consulting and execution. 

In previous roles David led Business Development for a $5B division of Medtronic (legacy Covidien) in their respiratory, monitoring and med/surg products covering 22 business lines. He ran deals in M&A, distribution, co-development and also executed minority equity investments. Prior to Medtronic, David was Director of Corporate Development at Hologic running strategy and executing deals across gyn surgery, breast health, and molecular diagnostics. 

https://www.linkedin.com/in/david-uffer-00a176/

Jonathan Norris

Managing Director, VC Relationship Managment, HSBC Innovation Banking

Jonathan Norris is a Managing Director at HSBC Innovation, with over two decades of experience in the healthcare and life sciences sector. A former litigation attorney, Jonathan has been immersed in healthcare investing since 1999, with a particular focus on equity and debt strategy across BioPharma, Medical Devices, Diagnostics/Tools, and Digital Health.

At HSBC Innovation, Jonathan advises both investors and executives by analyzing historical and current market trends, including venture investments, IPO activity, and M&A. He regularly supports C-level leadership with business planning, exit strategy, and access to capital, and is known for his insightful thought leadership on healthcare venture funding and deal flow.

Jonathan has authored numerous analyses on the flow of capital into the healthcare ecosystem and continues to be a trusted voice in the industry, helping shape strategic decision-making for both startups and investors.

https://www.linkedin.com/in/jonathan-norris-248556/

Diana Saraceni

Founder and Managing Partner, Panakes Partners

Diana Saraceni is a seasoned venture capitalist with over 20 years of experience in pan-European investments across Digital, Cleantech/Deep Tech, and Healthcare/Life Sciences. She is the Co-Founder and Managing Partner at Panakès Partners, where she plays a leading role in funding and scaling innovative startups.

Diana has successfully raised and managed multiple funds and has guided numerous portfolio companies to exits through trade sales and IPOs. Beyond investing, she actively contributes to the innovation ecosystem by serving on selection committees, chairing startup competitions, and advocating for greater gender balance in technology. She also lectures on Entrepreneurship and Venture Capital at leading academic institutions across Europe.

https://www.linkedin.com/in/diana-saraceni-74994/

Hosts:

Joseph Snyder

Head of Talent and Co-Founder, Lifeblood

https://www.linkedin.com/in/josephasnyder1/

Cristiano Fontana

Head of Advisory, Lifeblood

https://www.linkedin.com/in/cristiano-fontana-medtech-businessdevelopment/

Guests:

Thomas Busby

Director, Outcome Capital

Thomas F. Busby is a Director at Outcome Capital, having joined the Firm in 2015. Drawing from transactional experience spanning the breadth of life science verticals, Mr. Busby’s primary coverage and focus spans the medical device, digital health, and life sciences services segments.

Mr. Busby has advised dozens of senior management teams and Boards on a variety of complex strategic issues, ranging from transaction process considerations to valuation and transaction structure, value proposition communication and buyer analysis, along with the plethora of managerial challenges faced in executing complex corporate events. Devoted to the industry he serves, Mr. Busby has been published in leading industry publications, including: MedTech Strategist, Life Science Leader, and The Pharma Letter. Mr. Busby has also served as a panelist, moderator and judge for numerous industry events and is a Board Member of HealthTech Build, a Boston-based digital health innovation group. He also served as an External Advisory Board Member for the UMASS Chan Medical School Bridge Fund.

Umaima Ahmad

CEO, 52North

Umaima is CEO and co-founder of 52North, a multi-award winning med-tech company focused on improving urgent care. The company has raised over $11m in funding and its first product was awarded breakthrough status by the UK Government in 2024. Previously a business development professional, and a banking lawyer, Umaima has held a number of non-executive roles within health-tech. She is a seasoned negotiator of significant M&A and licensing transactions with values in the billions of dollars, involving pharmaceutical assets across multiple therapy areas which have had significant tangible impact on patient treatment pathways and health outcomes. Umaima is a graduate of King’s College London, the University of Strasbourg and BPP Law School and holds an MPhil in Bioscience Enterprise from the University of Cambridge.

https://www.linkedin.com/in/umaima-ahmad/

Tracy McNeal

CEO and President, Materna Medical

Tracy MacNeal is the CEO of Materna Medical. She is a chemical engineer, a Duke MBA, a healthcare entrepreneur, and a medical technology investor. A driver for health equity, Tracy also serves on the Board of Directors for AdvaMed, the national industry organization for medical devices, and leads their Women’s Health Equity Initiative. Tracy is President and CEO of Materna Medical, a novel, post-revenue OBGYN company with one product on the market and an exciting clinical stage product seeking to reduce maternal injury, shorten delivery time, reduce C-sections, and improve postpartum recovery for new moms.

https://www.linkedin.com/in/tracymacneal/

Martin Gomez

Partner, Goodwin Procter LLP

Martin Gomez is a partner in Goodwin’s Technology and Life Sciences Business Unit, specializing in intellectual property matters, and is a co-leader of the Firm’s MedTech and Artificial Intelligence practice groups. Martin focuses his practice on advising technology and life sciences companies of all sizes (including startups), and their investors, in corporate and especially intellectual property matters throughout the business life cycle, including new company formation, IP protection, fundraising, strat